At a glance
ClinicalIndex Comparison Record- ✓Histologically documented NSCLC with metastases (Stage IV or recurrent) or locally advanced Stage IIIB with malignant pleural effusion
- ✓At least 1 prior systemic therapy for metastatic disease required (prior adjuvant therapy for localized disease does not count)
- ✕Central lung lesions involving major blood vessels (arteries or veins)
- ✕History of Grade 2 or worse hemoptysis
- ✕Grade 1 hemoptysis within 30 days of entry
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later- Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating axitinib for Lung Neoplasms and Carcinoma, Non-small Cell Lung. Completed, enrolled 32 participants across 11 sites in 2 countries.
Detailed Summary
This is a Phase 2 study being conducted at multiple centers in the United States and Germany. Patients having non-small cell lung cancer that has spread to other parts of the body (i.e., metastatic) or is locally advanced (i.e., Stage IIIB with malignant pleural effusion) are eligible to participate. Patients must have disease that has been treated with at least 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for advanced non-small cell lung cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage
Study Details
Timeline
Interventions
Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.